GAITHERSBURG, Md., Feb. 6, 2017 /PRNewswire/ -- Altimmune, Inc., a
clinical stage immunotherapeutics company targeting infectious
diseases, announced today that Chief Executive Officer Bill Enright will present at the BIO CEO &
Investor Conference on Monday, February 13,
2017 at 4:00 PM ET. The
conference will be held at the Waldorf Astoria New York.
About Altimmune, Inc.
Altimmune is a clinical stage immunotherapeutics company focused on
the development of products to stimulate robust and durable immune
responses for the prevention and treatment of disease. The Company
has two proprietary platform technologies, RespirVec and Densigen,
each of which has been shown to activate the immune system in
distinctly different ways than traditional vaccines. Using these
technologies, Altimmune has developed three novel clinical stage
product candidates that potentially represent an entirely new
approach to harnessing the immune system. The Company's most
advanced product candidate, NasoVAX, is a Phase 2-ready
intranasally-delivered recombinant influenza vaccine offering broad
and rapid protection with potential for significant advantages over
traditional flu vaccines. The second most advanced product
candidate, HepTcell, is being tested as an immunotherapy for
patients chronically infected with hepatitis B and has the
potential to provide a functional cure. With the support of the
U.S. Biomedical Advanced Research and Development Authority, or
BARDA, the Company is developing a third product candidate,
NasoShield, a first-in-class anthrax vaccine designed to provide
rapid, stable protection after one intranasal administration. The
Company intends to leverage the RespirVec and Densigen platforms to
develop additional product candidates for a variety of
indications.
On January 19, 2017, the Company
announced the signing of a definitive agreement to merge with
PharmAthene, Inc. (NYSE MKT: PIP) in an all-stock transaction. The
combined company will be a fully-integrated and diversified
immunotherapeutics company with four clinical stage and one
preclinical stage programs.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/altimmune-to-present-at-the-bio-ceo--investor-conference-300402161.html
SOURCE Altimmune, Inc.